PT-141 10mg

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

Quickstart Highlights

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system — predominantly through the MC4 receptor — to influence sexual desire and arousal[5][6]. Unlike PDE5 inhibitors that work on blood flow, it engages a brain pathway. Bremelanotide is FDA-approved as Vyleesi, but only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women[1]; any use for erectile dysfunction or libido in men is off-label / research only. This page outlines an as-needed (PRN) subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks — presented for research and educational use only.

Add 2.0 mL bacteriostatic water to one 10 mg vial → 5 mg/mL (5,000 mcg/mL), a clean dilution for accurate PRN dosing.
1–2 mg taken ~45 minutes before activity. Maximum one dose per 24 hours and limited per week — this is PRN, not a daily course.
At 5 mg/mL, 1 unit = 50 mcg on a U-100 syringe; 1 mg = 20 units (0.20 mL) and 2 mg = 40 units (0.40 mL).
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.

Dosing & Reconstitution Guide

A single practical dilution with accurate as-needed dosing, step by step

As-Needed (PRN) Approach (2 mL = 5 mg/mL)

Dose	Timing	Volume (U-100 units / mL)
1 mg (test / starting dose)	~45 min before activity	20 units (0.20 mL)
1.5 mg (titrate if needed)	~45 min before activity	30 units (0.30 mL)
2 mg (typical effective dose)	~45 min before activity	40 units (0.40 mL)

Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration 5 mg/mL (5,000 mcg/mL).
Typical dose: 1–2 mg as needed, taken roughly 45 minutes before anticipated activity. This is per-administration, not daily therapy.
Easy measuring: At 5 mg/mL, 1 unit = 50 mcg on a U-100 syringe. So 1 mg reads at 20 units and 2 mg at 40 units — comfortable, easy-to-read volumes.
Limits: Maximum one dose per 24 hours, and keep weekly use limited; exceeding labeled frequency raised the risk of focal skin hyperpigmentation in studies.
Frequency: a single subcutaneous injection as needed, about 45 minutes before anticipated activity. Do not exceed one dose in 24 hours, and keep total use limited per week[1]. The FDA-approved Vyleesi regimen for HSDD in premenopausal women is a single 1.75 mg dose PRN; the figures here are practical research-reference measurements, not approved dosing for any other use.

Reconstitution Steps

Draw 2.0 mL of bacteriostatic water into a sterile syringe.

Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 2.0 mL dilution gives a clean 5 mg/mL so each milligram reads at exactly 20 units on a U-100 syringe. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

Supplies Needed

Quantities below assume as-needed (PRN) use over an 8–16 week window, with a 2 mg dose and the limit of one dose per 24 hours.

At 5 mg/mL, one 10 mg vial provides about five 2 mg doses, so plan vials by how often you use it.
~16 doses: ~4 vials
~24 doses: ~5 vials
~32 doses: ~7 vials
Per dose: 1 syringe
~16 doses: 16 syringes
~32 doses: 32 syringes
Use ~2.0 mL per 10 mg vial for reconstitution.
4 vials: ~8 mL → 1 bottle
7 vials: ~14 mL → 2 bottles
One for the vial stopper + one for the injection site per dose.
Per dose: 2 swabs
~32 doses: ~64 swabs → 1 box

Protocol Overview

A concise summary of the as-needed regimen, drawn from labeling and commonly cited reference protocols.

▪Goal: Raise sexual desire and reduce related distress; FDA-approved (as Vyleesi) only for HSDD in premenopausal women, shown in two Phase 3 RECONNECT trials[2]. Note the satisfying-sexual-events endpoint was mixed.
▪Schedule: Subcutaneous, as needed — one dose ~45 minutes before activity; maximum one dose per 24 hours and limited per week[1].
▪Dose Range: 1–2 mg per administration; the approved Vyleesi dose is 1.75 mg PRN.
▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial gives 5 mg/mL for accurate unit measurements.
▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.

Dosing Protocol

A practical as-needed approach with clear limits.

▪Start: Try a conservative test dose (1 mg) to gauge tolerability before using a full dose.
▪Titrate: Move toward 1.5–2 mg based on response and tolerability.
▪Timing: Inject ~45–60 minutes before anticipated activity; individuals may adjust slightly based on personal response.
▪Do not exceed: one dose per 24 hours; keep weekly use limited — frequent dosing increased focal hyperpigmentation in studies.
▪Site: Subcutaneous in the abdomen or thigh; rotate sites between uses.

Storage Instructions

Correct storage is what preserves the peptide’s stability and activity.

▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[9].
▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for short-term holding; do not freeze the mixed solution, as freezing can denature peptides[10].
▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.

Important Notes

Practical points that keep as-needed administration safe and consistent.

▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[3].
▪Site rotation: Move between abdomen, thighs and upper arms to reduce local reactions and maintain absorption[3].
▪Cardiovascular caution: Bremelanotide causes transient increases in blood pressure and a small drop in heart rate; the label advises against use in people with uncontrolled hypertension or known cardiovascular disease[1].
▪Common side effects: Nausea (most frequent), flushing, headache, and injection-site reactions; nausea is usually worst with the first few doses[1].
▪Approval scope: FDA approval (Vyleesi) covers only HSDD in premenopausal women. Use for erectile dysfunction or libido in men is off-label / research and not an approved indication.

How This Works

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts mainly through the MC4 receptor in the central nervous system[5][6]. It engages hypothalamic circuits tied to sexual desire and autonomic arousal — a brain pathway, fundamentally different from PDE5 inhibitors (such as sildenafil) that act on blood flow.

In two Phase 3 RECONNECT trials in premenopausal women with HSDD, PRN 1.75 mg subcutaneous dosing improved validated measures of sexual desire and reduced desire-related distress versus placebo[2]. Honest framing matters here: the co-primary endpoint for satisfying sexual events was mixed, so the benefit is best described as a modest, real effect on desire and distress rather than a dramatic change.
Because MC4R also participates in appetite and energy balance, exploratory work has examined whether melanocortin agonism affects caloric intake and body weight under intensive dosing[7]. That is mechanistic and early-stage — not an approved use.
Important caveat: bremelanotide is FDA-approved — but the approval (Vyleesi) is specifically and only for acquired, generalized HSDD in premenopausal women. Use in men, for erectile dysfunction, or for general libido is off-label and investigational, and is presented here for research and educational purposes only.
Subcutaneous delivery is standard for this molecule and supports practical at-home administration with small injection volumes[8].

Lifestyle Factors

Habits that may support outcomes alongside the protocol.

▪Timing & communication: Plan the ~45-minute lead time and align expectations with a partner so use matches anticipated activity.
▪Manage nausea: Since nausea is the most common effect, a light meal and unhurried timing can make the first few uses easier.
▪Overall well-being: Sleep, stress management and exercise support desire and general sexual health independent of any peptide.
▪Blood pressure awareness: Given the transient BP rise, avoid stacking with other agents that raise blood pressure and monitor if you are sensitive.

Potential Benefits & Side Effects

What the clinical evidence describes; effects are modest and individual results vary.

▪Sexual desire (Phase 3): Improved desire and reduced desire-related distress in premenopausal women with HSDD versus placebo[2].
▪Central mechanism: Works on a brain (MC4R) pathway rather than blood flow, so it targets desire/arousal directly[6].
▪Honest framing: The benefit is modest — the satisfying-sexual-events endpoint was mixed, so PT-141 is not a guaranteed or dramatic effect[2].
▪Off-label note: Reported use for libido/ED in men is not established or approved — that data is anecdotal and investigational.
▪Nausea, flushing, headache: The most common effects; nausea is frequent and usually worst with the first few doses[1].
▪Transient blood-pressure rise: A short-lived increase in blood pressure with a small heart-rate drop; relevant if you have cardiovascular risk[1].
▪Focal hyperpigmentation: Darkening of skin/gums can occur, and more frequent dosing than labeled increased this risk[1].

Injection Technique

General subcutaneous technique, following established clinical best-practice guidance[3][4].

▪Wash your hands well with soap and water.
▪Wipe the vial stopper with an alcohol swab and let it air-dry.
▪Choose a site (abdomen or thigh) and clean it with a fresh alcohol swab, letting it dry fully[4].
▪Draw the intended dose (e.g., 40 units for 2 mg), then check for air bubbles and push any out.
▪Pinch a skinfold at the chosen site between thumb and forefinger.
▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[3].
▪Skip aspiration for subcutaneous shots — it isn’t needed[3].
▪Press the plunger slowly and steadily until it’s fully down.
▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
▪Return the reconstituted vial to the fridge right away.
▪Rotate the injection site between uses to prevent irritation.
▪Watch the site for excess redness, swelling, or signs of infection.

Recommended Source

For high-purity research peptides, we point researchers to Prime Lab Peptides for PT-141 (10 mg).

▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA. Open source
▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
Shop at Prime Lab Peptides →

References

Reference-derived details for PT-141 10mg.

PT-141 (10mg Vial) Dosage Protocol Open source
1 FDA Prescribing Information — Vyleesi (bremelanotide) Official label: PRN 1.75 mg SC for HSDD in premenopausal women, dosing limits (max 1/24 h, 8/month), and precautions including transient blood-pressure increase and focal hyperpigmentation. View Source ↗ Open source
2 Obstetrics & Gynecology (2019) — RECONNECT trials Two Phase 3 randomized trials of bremelanotide 1.75 mg SC PRN for HSDD; improved desire and distress, with a mixed satisfying-sexual-events endpoint. View Source ↗ Open source
3 CDC — Vaccine Administration / Subcutaneous Technique Subcutaneous injection technique: 45–90° insertion, site selection, and no-aspiration guidance. View Source ↗ Open source
4 MedlinePlus (NIH) — Subcutaneous Injections Patient instructions for subcutaneous injections: angle, site rotation, and hygiene. View Source ↗ Open source
5 Clinical Pharmacology — Bremelanotide Review Pharmacology of bremelanotide as a melanocortin receptor agonist with central (CNS) action on sexual desire pathways. View Source ↗ Open source
6 Front. Neuroscience (2019) — MC4R pathway Melanocortin-4 receptor mechanisms and therapeutic targeting relevant to sexual desire and arousal. View Source ↗ Open source
7 Diabetes, Obesity & Metabolism (2022) — Spana et al. Phase 1 exploratory work: bremelanotide and MC4R agonism affecting caloric intake and body weight under intensive dosing (not an approved use). View Source ↗ Open source
8 Usach et al., Advances in Therapy (2019) Subcutaneous injection review: typical and upper-range volumes and pain considerations for at-home delivery. View Source ↗ Open source
9 Peptide Storage Guide (GenScript) Best practices for storing lyophilized peptides: temperature, humidity, and light protection. View Source ↗ Open source
10 Cheng et al., AAPS Open (2024) Lyophilized protein drug products; reconstituted-liquid stability commonly assessed at 2–8 °C. View Source ↗ Open source
11 Prime Lab Peptides — PT-141 (10 mg) PT-141 (10 mg) product page — purity specifications and certificates of analysis. View Source ↗ Open source

Contents